Education
About Us
Working with TipRanks
Follow Us
Senti Biosciences (SNTI)
NASDAQ:SNTI
SNTI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.52 - $16.94
Previous CloseN/A
Volume20.15K
Average Volume (3M)28.09K
Market Cap
$85.23M
Enterprise Value$26.83M
Total Cash (Recent Filing)$56.03M
Total Debt (Recent Filing)$22.73M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
May 07, 2025EPS Estimate
-3.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.08
Shares Outstanding25,986,000
10 Day Avg. Volume23,019
30 Day Avg. Volume28,089
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.54
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.59
Forecast
1Y Price Target
$10.00Price Target Upside172.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Senti Biosciences News
PremiumCompany Announcements
Senti Bio Reports Promising Trial Results and Financial Growth
PremiumCompany Announcements
Senti Biosciences Expands Board with New Appointment
PremiumCompany Announcements
Senti Biosciences Appoints New CFO Jay Cross---
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst's recommendation for Senti Biosciences is a 'Buy' with a price target increased to $10.
Clinical Trial ResultsInitial data from the phase I trial of SENTI-202 showed that 2 out of 3 patients achieved complete remission, which is seen as encouraging due to the link between MRD-negative CR and better outcomes in AML.
Financing And DevelopmentSenti additionally disclosed a $37.6 mm PIPE financing, which should support the company's continued execution on the '202 program.
Bears Say
Cash PositionThe company ended the quarter with a limited cash position of $10.5 million, which has decreased from the previous quarter.
Treatment ResponseThere is a lack of clarity about why one patient did not respond to the treatment, particularly given the presence of TP53-mutated AML, which is difficult to treat.
Uncertainty In Trial DataThe current dataset is small and with limited follow-up, leaving some uncertainty about the durability and response factors of SENTI-202.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SNTI FAQ
What was Senti Biosciences’s price range in the past 12 months?
Senti Biosciences lowest stock price was $1.52 and its highest was $16.94 in the past 12 months.
What is Senti Biosciences’s market cap?
Senti Biosciences’s market cap is $85.23M.
When is Senti Biosciences’s upcoming earnings report date?
Senti Biosciences’s upcoming earnings report date is May 07, 2025 which is in 20 days.
How were Senti Biosciences’s earnings last quarter?
Senti Biosciences released its earnings results on Mar 20, 2025. The company reported -$0.67 earnings per share for the quarter, beating the consensus estimate of -$3.13 by $2.46.
Is Senti Biosciences overvalued?
According to Wall Street analysts Senti Biosciences’s price is currently Undervalued.
Does Senti Biosciences pay dividends?
Senti Biosciences does not currently pay dividends.
What is Senti Biosciences’s EPS estimate?
Senti Biosciences’s EPS estimate is -3.13.
How many shares outstanding does Senti Biosciences have?
Senti Biosciences has 25,986,000 shares outstanding.
What happened to Senti Biosciences’s price movement after its last earnings report?
Senti Biosciences reported an EPS of -$0.67 in its last earnings report, beating expectations of -$3.13. Following the earnings report the stock price went down -3.039%.
Which hedge fund is a major shareholder of Senti Biosciences?
Currently, no hedge funds are holding shares in SNTI
---
Senti Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (172.48% Upside)
$10.00 (172.48% Upside)
Hedge Fund Trend
Decreased
By 176.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $49.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.84%
12-Months-Change
Fundamentals
Return on Equity
-89.73%
Trailing 12-Months
Asset Growth
-18.11%
Trailing 12-Months
Company Description
Senti Biosciences
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
---
SNTI Stock 12 Month Forecast
Average Price Target
$10.00
▲(172.48% Upside)
Technical Analysis
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Verve Therapeutics
―
Best Analysts Covering SNTI
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-52.07%
reiterated a buy rating 5 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -52.07% per trade.
---